A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma

Abstract 18F-fluorodeoxyglucose PET-CT may guide treatment decisions in patients with oesophageal adenocarcinoma (OAC). This study evaluated the added value of maximum standardised uptake value (SUVmax) to a novel DNA-damage immune response (DDIR) assay to improve pathological response prediction. T...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kieran G. Foley, Anita Lavery, Eoin Napier, David Campbell, Martin M. Eatock, Richard D. Kennedy, Kevin M. Bradley, Richard C. Turkington
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/335f4a45c8e3412591391e3d999c13de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:335f4a45c8e3412591391e3d999c13de
record_format	dspace
spelling	oai:doaj.org-article:335f4a45c8e3412591391e3d999c13de2021-12-02T17:12:25ZA DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma10.1038/s41598-021-92545-w2045-2322https://doaj.org/article/335f4a45c8e3412591391e3d999c13de2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-92545-whttps://doaj.org/toc/2045-2322Abstract 18F-fluorodeoxyglucose PET-CT may guide treatment decisions in patients with oesophageal adenocarcinoma (OAC). This study evaluated the added value of maximum standardised uptake value (SUVmax) to a novel DNA-damage immune response (DDIR) assay to improve pathological response prediction. The diagnostic accuracy of PET response and the prognostic significance of PET metrics for recurrence-free survival (RFS) and overall survival (OS) were assessed. This was a retrospective, single-centre study of OAC patients treated with neo-adjuvant chemotherapy from 2003 to 2014. SUVmax was recorded from baseline and repeat PET-CT after completion of pre-operative chemotherapy. Logistic regression models tested the additional predictive value of PET metrics combined with the DDIR assay for pathological response. Cox regression models tested the prognostic significance of PET metrics for RFS and OS. In total, 113 patients were included; 25 (22.1%) were DDIR positive and 88 (77.9%) were DDIR negative. 69 (61.1%) were PET responders (SUVmax reduction of 35%) and 44 (38.9%) were PET non-responders. After adding PET metrics to DDIR status, post-chemotherapy SUVmax (hazard ratio (HR) 0.75, p = 0.02), SUVmax change (HR 1.04, p = 0.003) and an optimum SUVmax reduction of 46.5% (HR 4.36, p = 0.021) showed additional value for predicting pathological response. The optimised SUVmax threshold was independently significant for RFS (HR 0.47, 95% CI 0.26–0.85, p = 0.012) and OS (HR 0.51, 95% CI 0.26–0.99, p = 0.047). This study demonstrated the additional value of PET metrics, when combined with a novel DDIR assay, to predict pathological response in OAC patients treated with neo-adjuvant chemotherapy. Furthermore, an optimised SUVmax reduction threshold for pathological response was calculated and was independently significant for RFS and OS.Kieran G. FoleyAnita LaveryEoin NapierDavid CampbellMartin M. EatockRichard D. KennedyKevin M. BradleyRichard C. TurkingtonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kieran G. Foley Anita Lavery Eoin Napier David Campbell Martin M. Eatock Richard D. Kennedy Kevin M. Bradley Richard C. Turkington A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
description	Abstract 18F-fluorodeoxyglucose PET-CT may guide treatment decisions in patients with oesophageal adenocarcinoma (OAC). This study evaluated the added value of maximum standardised uptake value (SUVmax) to a novel DNA-damage immune response (DDIR) assay to improve pathological response prediction. The diagnostic accuracy of PET response and the prognostic significance of PET metrics for recurrence-free survival (RFS) and overall survival (OS) were assessed. This was a retrospective, single-centre study of OAC patients treated with neo-adjuvant chemotherapy from 2003 to 2014. SUVmax was recorded from baseline and repeat PET-CT after completion of pre-operative chemotherapy. Logistic regression models tested the additional predictive value of PET metrics combined with the DDIR assay for pathological response. Cox regression models tested the prognostic significance of PET metrics for RFS and OS. In total, 113 patients were included; 25 (22.1%) were DDIR positive and 88 (77.9%) were DDIR negative. 69 (61.1%) were PET responders (SUVmax reduction of 35%) and 44 (38.9%) were PET non-responders. After adding PET metrics to DDIR status, post-chemotherapy SUVmax (hazard ratio (HR) 0.75, p = 0.02), SUVmax change (HR 1.04, p = 0.003) and an optimum SUVmax reduction of 46.5% (HR 4.36, p = 0.021) showed additional value for predicting pathological response. The optimised SUVmax threshold was independently significant for RFS (HR 0.47, 95% CI 0.26–0.85, p = 0.012) and OS (HR 0.51, 95% CI 0.26–0.99, p = 0.047). This study demonstrated the additional value of PET metrics, when combined with a novel DDIR assay, to predict pathological response in OAC patients treated with neo-adjuvant chemotherapy. Furthermore, an optimised SUVmax reduction threshold for pathological response was calculated and was independently significant for RFS and OS.
format	article
author	Kieran G. Foley Anita Lavery Eoin Napier David Campbell Martin M. Eatock Richard D. Kennedy Kevin M. Bradley Richard C. Turkington
author_facet	Kieran G. Foley Anita Lavery Eoin Napier David Campbell Martin M. Eatock Richard D. Kennedy Kevin M. Bradley Richard C. Turkington
author_sort	Kieran G. Foley
title	A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
title_short	A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
title_full	A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
title_fullStr	A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
title_full_unstemmed	A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
title_sort	dna-damage immune response assay combined with pet biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/335f4a45c8e3412591391e3d999c13de
work_keys_str_mv	AT kierangfoley adnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT anitalavery adnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT eoinnapier adnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT davidcampbell adnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT martinmeatock adnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT richarddkennedy adnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT kevinmbradley adnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT richardcturkington adnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT kierangfoley dnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT anitalavery dnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT eoinnapier dnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT davidcampbell dnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT martinmeatock dnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT richarddkennedy dnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT kevinmbradley dnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma AT richardcturkington dnadamageimmuneresponseassaycombinedwithpetbiomarkerspredictsresponsetoneoadjuvantchemotherapyandsurvivalinoesophagealadenocarcinoma
_version_	1718381368782618624

A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma

Ejemplares similares